Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

Clinical trial NCT04100434 · UNKNOWN

Trial details

NCT number: NCT04100434
Sponsor: Tianjin Chest Hospital
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Acute Coronary Syndrome Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

Start date: 2021-01-01
Primary completion: 2022-06-01
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.